B+
Bull case
25%
Probability
Target price
$23.00
+58.9% vs current
ANGO
AngioDynamicsANasdaq / Health Care Equipment & Services
Last Price
At close
2026-07-18
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
55%
Probability
Target price
$18.50
+27.9% vs current
B-
Bear case
20%
Probability
Target price
$10.50
-27.4% vs current
AI sentiment snapshot
Latest data as of 2026-07-17
Recent news sentiment (30D)
+30.0
Positive
Company
-
Unavailable
Macro
+30.0
Positive
Pulse
-
Unavailable
Sentiment proxy
+78.7
Score
AI commentary
Post-earnings tone is constructive: company results showed strong Med Tech growth and FY2027 guidance, while Canaccord raised its target; Investing.com displayed ANGO up 11.31% in its July 14 update ([source](https://www.investing.com/news/analyst-ratings/canaccord-raises-angiodynamics-stock-price-target-on-nanoknife-strength-93CH-4791469)). Social, options, short-interest, and employee-sentiment data were unavailable, so conviction remains moderate despite the positive evidence.
RankAlpha Sentiment Codex - 2026-07-17
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-07-31catalystPost-earnings beat and positive target revisionHigh impact
Q4 FY2026 revenue was $86.6 million, Med Tech grew 16.7%, and adjusted EPS loss was $0.07 versus a reported $0.09 consensus estimate. Canaccord raised its target to $20 from $16 while maintaining Buy [#SEC-8K-2026-07-14].
2026-10-15eventFY2027 guidance executionHigh impact
Management guided to FY2027 sales of $336–341 million, Med Tech growth of 12%–15%, gross margin of 54%–55%, and adjusted EBITDA of $13–16 million. Quarterly execution against this outlook is the key validation event [#SEC-8K-2026-07-14].
2026-10-15catalystMechanical thrombectomy and tariff pressureHigh impact
Q4 mechanical thrombectomy sales declined 1.1%, with AngioVac down 15.8%; management expects a broadly similar but dynamic tariff impact in FY2027 [#SEC-8K-2026-07-14].
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-17 • Updated nightlySource: Internal modelMethodology